Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Eascra Biotech
AddedFeb 16, 2024
UpdatedJun 18, 2026
Eascra Biotech

Eascra Biotech

Seed

Eascra Biotech: DNA-inspired nanotech solutions for chronic conditions, enhancing drug efficacy.

HQ
Boston, MA, US
Founded
2022
Overview
Compare
Fundraising
Employees

Eascra Biotech creates Janus base nanomaterials based on DNA nanotechnology that are highly effective and super biocompatible for articular cartilage, central nervous system disorders, solid tumors, and other chronic conditions.

Its three generations of DNA-inspired nanotubes are a low-cost, scalable alternative to existing options. Its Janus nanotechnologies can be tailored to improve the therapeutic efficacy of drug treatments for a variety of chronic conditions and medical needs.

Eascra Biotech - Similar Companies

Atom Bioworks logo

Atom Bioworks

atombioworks.com

Nanotransfer logo

Nanotransfer

nanotransfer.bio

Advanced NanoTherapies logo

Advanced NanoTherapies

Aptabridge logo

Aptabridge

aptabridge.com

BioNanovations logo

BioNanovations

Optimeos Life Sciences logo

Optimeos Life Sciences

optimeos.com

Transcera logo

Transcera

Escape Bio logo

Escape Bio

escapebio.com

NanoMosaic logo

NanoMosaic

Nano RED logo

Nano RED

Nanocan Therapeutics logo

Nanocan Therapeutics

OmegaGenesis logo

OmegaGenesis

Nanite logo

Nanite

nanitebio.com

Cocoon Biotech logo

Cocoon Biotech

cocoonbiotech.com

Alaya.bio logo

Alaya.bio

alaya.bio

Eascra Biotech - Quick Facts

Who are Eascra Biotech's competitors?

Companies similar to Eascra Biotech include Atom Bioworks, Nanotransfer, Advanced NanoTherapies and Aptabridge.

When was Eascra Biotech founded?

Eascra Biotech was founded in 2022.

Where is Eascra Biotech's headquarters located?

Eascra Biotech's headquarters is located in Boston, MA, US.

When was Eascra Biotech's last funding round?

Eascra Biotech's most recent funding round was for $1.8M (USD) in December 2022.

How much has Eascra Biotech raised to-date?

As of Dec 6, 2022, Eascra Biotech has raised a total of $1.8M (USD).

How many employees does Eascra Biotech have?

Eascra Biotech has 5 employees as of Feb 4, 2024.

Eascra Biotech - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
  • Nanotechnology
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Licensing
  • Recurring
Customer
  • Enterprise
Main Product
  • Drug Delivery
  • Nanomaterials
Tags
  • Healthcare
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research